189 related articles for article (PubMed ID: 28319420)
1. Modelling long-term evolution of chitotriosidase in non-neuronopathic Gaucher disease.
Drugan C; Drugan TC; Grigorescu-Sido P; Naşcu I
Scand J Clin Lab Invest; 2017 Jul; 77(4):275-282. PubMed ID: 28319420
[TBL] [Abstract][Full Text] [Related]
2. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.
van Dussen L; Hendriks EJ; Groener JE; Boot RG; Hollak CE; Aerts JM
J Inherit Metab Dis; 2014 Nov; 37(6):991-1001. PubMed ID: 24831585
[TBL] [Abstract][Full Text] [Related]
3. [Comparison and clinical application of two methods for determination of plasma chitotriosidase activity].
Wang Y; Zhang HW; Ye J; Qiu WJ; Han LS; Gu XF
Zhonghua Er Ke Za Zhi; 2012 Nov; 50(11):834-8. PubMed ID: 23302614
[TBL] [Abstract][Full Text] [Related]
4. Different dose-dependent correction of MIP-1beta and chitotriosidase during initial enzyme replacement therapy.
van Breemen MJ; de Fost M; Maas M; Wiersma MG; Hollak CE; Poll LW; Vom Dahl S; Boot RG; Aerts JM
J Inherit Metab Dis; 2009 Apr; 32(2):274-9. PubMed ID: 19255873
[TBL] [Abstract][Full Text] [Related]
5. Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model.
Vigan M; Stirnemann J; Caillaud C; Froissart R; Boutten A; Fantin B; Belmatoug N; Mentré F
Orphanet J Rare Dis; 2014 Jun; 9():95. PubMed ID: 24980507
[TBL] [Abstract][Full Text] [Related]
6. Plasma chitotriosidase activity versus CCL18 level for assessing type I Gaucher disease severity: protocol for a systematic review with meta-analysis of individual participant data.
Raskovalova T; Deegan PB; Yang R; Pavlova E; Stirnemann J; Labarère J; Zimran A; Mistry PK; Berger M
Syst Rev; 2017 Apr; 6(1):87. PubMed ID: 28427477
[TBL] [Abstract][Full Text] [Related]
7. Serum chitotriosidase activity in Gaucher patients on enzyme replacement therapy (ERT).
Czartoryska B; Tylki-Szymańska A; Górska D
Clin Biochem; 1998 Jul; 31(5):417-20. PubMed ID: 9721443
[TBL] [Abstract][Full Text] [Related]
8. Chitotriosidase variants in patients with Gaucher disease. Implications for diagnosis and therapeutic monitoring.
Irún P; Alfonso P; Aznarez S; Giraldo P; Pocovi M
Clin Biochem; 2013 Dec; 46(18):1804-7. PubMed ID: 24060732
[TBL] [Abstract][Full Text] [Related]
9. Chitotriosidase genotype and plasma activity in patients type 1 Gaucher's disease and their relatives (carriers and non carriers).
Giraldo P; Cenarro A; Alfonso P; Pérez-Calvo JI; Rubio-Félix D; Giralt M; Pocoví M
Haematologica; 2001 Sep; 86(9):977-84. PubMed ID: 11532627
[TBL] [Abstract][Full Text] [Related]
10. A 20-Year Longitudinal Study of Plasma Chitotriosidase Activity in Treated Gaucher Disease Type 1 and 3 Patients-A Qualitative and Quantitative Approach.
Szymańska-Rożek P; Czartoryska B; Kleinotiene G; Lipiński P; Tylki-Szymańska A; Ługowska A
Biomolecules; 2023 Feb; 13(3):. PubMed ID: 36979371
[TBL] [Abstract][Full Text] [Related]
11. Plasma chitotriosidase activity versus plasma glucosylsphingosine in wide spectrum of Gaucher disease phenotypes - A statistical insight.
Tylki-Szymańska A; Szymańska-Rożek P; Hasiński P; Ługowska A
Mol Genet Metab; 2018 Apr; 123(4):495-500. PubMed ID: 29530534
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of neopterin as a biomarker for the monitoring of Gaucher disease patients.
Drugan C; Drugan TC; Miron N; Grigorescu-Sido P; Naşcu I; Cătană C
Hematology; 2016 Jul; 21(6):379-86. PubMed ID: 26903266
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of Gaucher patients with a novel chitotriosidase assay.
Schoonhoven A; Rudensky B; Elstein D; Zimran A; Hollak CE; Groener JE; Aerts JM
Clin Chim Acta; 2007 Jun; 381(2):136-9. PubMed ID: 17408605
[TBL] [Abstract][Full Text] [Related]
14. [Effect of enzyme replacement therapy on lipid profile in patients with Gaucher's disease].
Alfonso P; Cenarro A; Pérez-Calvo JI; Puzo J; Giralt M; Giraldo P; Pocoví M
Med Clin (Barc); 2003 May; 120(17):641-6. PubMed ID: 12747811
[TBL] [Abstract][Full Text] [Related]
15. [Plasma chitotriosidase activity in Argentinian patients with Gaucher disease, various lysosomal diseases and other inherited metabolic disorders].
Dodelson de Kremer R; Paschini de Capra A; Angaroni CJ; Giner de Ayala A
Medicina (B Aires); 1997; 57(6):677-84. PubMed ID: 9674188
[TBL] [Abstract][Full Text] [Related]
16. Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases.
Aerts JM; Hollak CE; van Breemen M; Maas M; Groener JE; Boot RG
Acta Paediatr Suppl; 2005 Mar; 94(447):43-6; discussion 37-8. PubMed ID: 15895711
[TBL] [Abstract][Full Text] [Related]
17. Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease.
Stirnemann J; Boutten A; Vincent C; Mekinian A; Heraoui D; Fantin B; Fain O; Mentré F; Belmatoug N
Blood Cells Mol Dis; 2011 Jan; 46(1):34-8. PubMed ID: 21084203
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
Ceravolo F; Grisolia M; Sestito S; Falvo F; Moricca MT; Concolino D
J Med Case Rep; 2017 Jan; 11(1):19. PubMed ID: 28103924
[TBL] [Abstract][Full Text] [Related]
19. Macrophage-derived soluble CD163 level in young patients with Gaucher disease: relation to phenotypes, disease severity and complications.
Adly AAM; Ismail EAR; Ibraheem TM
Int Immunopharmacol; 2015 Feb; 24(2):416-422. PubMed ID: 25587690
[TBL] [Abstract][Full Text] [Related]
20. [Chitotriosidase of human macrophages and mammalian chitinases: biological functions and abnormalities in pathology].
Korolenko TA; Cherkanova MS
Vestn Ross Akad Med Nauk; 2009; (11):39-45. PubMed ID: 20017407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
